[
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech Seeks an Experienced Quality Director",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech is recruiting for a Quality Director position. This is a corporate hiring announcement with no specific drug, technology, or therapeutic area details provided in the ",
    "url": "https://www.delsitech.com/delsitech-seeks-an-experienced-quality-director/",
    "date": "2025-12-08",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech is Hiring a Process Engineer",
    "summary": "",
    "url": "https://www.delsitech.com/delsitech-is-hiring-a-process-engineer/",
    "date": "2025-12-08",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "DelSiTech announces a leadership change. Carl-Åke Carlsson, CEO of DelSiTech, leaves the company and the Board nominates Martti Hedman as Interim CEO.",
    "summary": "```json\n{\n  \"summary\": \"DelSiTech announces a leadership transition with CEO Carl-Åke Carlsson departing the company. The Board has appointed Martti Hedman to serve as Interim CEO following Carlsson's",
    "url": "https://www.delsitech.com/delsitech-announces-a-leadership-change-carl-ake-carlsson-ceo-of-delsitech-leaves-the-company-and-the-board-nominates-martti-hedman-as-interim-ceo/",
    "date": "2025-12-08",
    "companies_detected": [
      "DelSiTech"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Appointment of Outi Heikkilä as Chief Operations Officer",
    "summary": "",
    "url": "https://www.delsitech.com/appointment-of-outi-heikkila-as-chief-operations-officer/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "summary": "```json\n{\n  \"summary\": \"Partnership Opportunities in Drug Delivery 2025 is a conference scheduled to take place in Boston on October 27-28. The event focuses on drug delivery partnership opportunities",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress Europe 2025 Amsterdam, October 13-16",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress Europe 2025 will be held in Amsterdam from October 13-16. This is a conference event focused on vaccine development and related topics in the pharmac",
    "url": "https://www.delsitech.com/world-vaccine-congress-europe-2025-amsterdam-october-13-16/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Drug Delivery and Formulation Summit 2025 Boston, September 15-16",
    "summary": "```json\n{\n  \"summary\": \"The Drug Delivery and Formulation Summit 2025 will be held in Boston on September 15-16. This industry conference will focus on drug delivery and formulation technologies. No s",
    "url": "https://www.delsitech.com/drug-delivery-and-formulation-summit-2025-boston-september-15-16/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "CRS Annual Meeting & Exposition 2025 Philadelphia, July 14-18",
    "summary": "```json\n{\n  \"summary\": \"The Controlled Release Society (CRS) is holding its Annual Meeting & Exposition in Philadelphia from July 14-18, 2025. This is a scientific conference focused on drug delivery ",
    "url": "https://www.delsitech.com/crs-annual-meeting-exposition-2025-philadelphia-july-14-18/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "summary": "",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "World Vaccine Congress 2025 Washington, April 21-24",
    "summary": "```json\n{\n  \"summary\": \"The World Vaccine Congress 2025 will be held in Washington from April 21-24. This is a conference event focused on vaccine development and related topics. No specific companies",
    "url": "https://www.delsitech.com/world-vaccine-congress-2025-washington-april-21-24/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Merck outbid three competitors in Cidara acquisition — new filing",
    "summary": "```json\n{\n  \"summary\": \"Merck won a competitive bidding process to acquire Cidara Therapeutics, outbidding three other pharmaceutical companies with an offer nearly 20% higher than competitors. The ac",
    "url": "https://endpoints.news/merck-outbid-three-competitors-in-cidara-acquisition-new-filing/",
    "date": "2025-12-08",
    "companies_detected": [
      "Cidara Therapeutics"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results",
    "summary": "```json\n{\n  \"summary\": \"Structure Therapeutics reported that its oral GLP-1 pill achieved a placebo-adjusted weight loss of 11.3% at approximately 8.5 months in obesity patients. The results are compe",
    "url": "https://endpoints.news/structure-therapeutics-obesity-pill-stacks-up-with-novo-and-lilly-ascletis-also-reports-early-results/",
    "date": "2025-12-08",
    "companies_detected": [
      "Eli Lilly",
      "Novo Nordisk"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Mirum to pay $620M for Bluejay and its hepatitis D antibody",
    "summary": "```json\n{\n  \"summary\": \"Mirum Pharmaceuticals is acquiring Bluejay Therapeutics for $620 million upfront to gain access to brelovitug, a late-stage monoclonal antibody treatment for chronic hepatitis ",
    "url": "https://endpoints.news/mirum-to-pay-620m-for-bluejay-and-its-hepatitis-d-antibody/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Updated: Wave Life Sciences says its RNA obesity shot cuts fat and retains muscle, but appears to lag Lilly’s",
    "summary": "",
    "url": "https://endpoints.news/wave-life-sciences-says-its-rna-obesity-shot-cuts-fat-but-retains-muscle/",
    "date": "2025-12-08",
    "companies_detected": [
      "Eli Lilly",
      "Novo Nordisk"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Kymera's pill looks competitive to Dupixent in Phase 1b eczema study",
    "summary": "",
    "url": "https://endpoints.news/kymeras-pill-looks-competitive-to-dupixent-in-phase-1b-eczema-study/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Kallyope heads to Phase 3 with migraine drug after mid-stage success",
    "summary": "",
    "url": "https://endpoints.news/kallyope-heads-to-phase-3-with-migraine-drug-after-mid-stage-success/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: Star Therapeutics details early data for blood disorder shot, weighs IPO",
    "summary": "```json\n{\n  \"summary\": \"Star Therapeutics presented early-stage data at ASH25 showing that its once-monthly injection for von Willebrand disease significantly reduced bleeding rates in a preliminary s",
    "url": "https://endpoints.news/ash25-star-therapeutics-details-early-data-for-blood-disorder-shot-weighs-ipo/",
    "date": "2025-12-07",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China",
    "summary": "```json\n{\n  \"summary\": \"AstraZeneca presented preliminary data at ASH25 showing their dual-targeting CAR-T cell therapy achieved similar response rates in Western cancer patients as previously observe",
    "url": "https://endpoints.news/astrazenecas-dual-targeting-car-t-sees-similar-responses-in-western-patients-as-in-china/",
    "date": "2025-12-06",
    "companies_detected": [
      "AstraZeneca"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "#ASH25: As one door closes for Regeneron’s lymphoma bispecific, another reopens",
    "summary": "```json\n{\n  \"summary\": \"Regeneron is experiencing another regulatory challenge in obtaining US approval for odronextamab, its bispecific antibody treatment for lymphoma. The company has faced a series",
    "url": "https://endpoints.news/ash25-as-one-door-closes-for-regenerons-lymphoma-bispecific-another-reopens/",
    "date": "2025-12-06",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Apple Tree Partners scores legal win against alleged holdout Russian investor",
    "summary": "```json\n{\n  \"summary\": \"Apple Tree Partners, a biotech investor, has won a court case against its main funder, a Russian investor who allegedly held out. This legal victory resolves months of uncertai",
    "url": "https://endpoints.news/apple-tree-partners-scores-legal-win-against-alleged-holdout-russian-investor/",
    "date": "2025-12-06",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and more",
    "summary": "",
    "url": "https://endpoints.news/acip-vote-more-fda-turnover-introducing-endpoints-signal-arch-parker-institute-building-next-cancer-bet-and-more/",
    "date": "2025-12-06",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations",
    "summary": "```json\n{\n  \"summary\": \"ORIC Pharmaceuticals reported encouraging early trial results for its oral lung cancer drug as first- and second-line treatment in patients with a specific genetic mutation. Ho",
    "url": "https://endpoints.news/orics-lung-cancer-pill-shows-promise-in-some-settings-but-is-dropped-for-her2-mutations/",
    "date": "2025-12-06",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Bristol Myers expands Breyanzi approval to marginal zone lymphoma",
    "summary": "```json\n{\n  \"summary\": \"Bristol Myers Squibb received FDA approval to expand the use of Breyanzi, a CAR-T cell therapy, to treat marginal zone lymphoma. This marks the first CAR-T therapy approved for",
    "url": "https://endpoints.news/bristol-myers-expands-breyanzi-approval-to-marginal-zone-lymphoma/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "ACIP drops universal hepatitis B birth dose recommendation",
    "summary": "",
    "url": "https://endpoints.news/acip-drops-universal-hepatitis-b-birth-dose-recommendation/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "NICE adds further details on how the UK will pay more for drugs",
    "summary": "",
    "url": "https://endpoints.news/nice-adds-further-details-on-how-the-uk-will-pay-more-for-drugs/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "DDS"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara",
    "summary": "",
    "url": "https://endpoints.news/denali-drug-hold-intercept-layoffs-capital-raises-for-immatics-capricor-and-protara/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Rapport shares updated results from Phase 2 study of seizure drug",
    "summary": "```json\n{\n  \"summary\": \"Rapport Therapeutics announced updated Phase 2 clinical trial results for its seizure drug candidate, demonstrating consistent efficacy over time across varying levels of disea",
    "url": "https://endpoints.news/rapport-shares-updated-results-from-phase-2-study-of-seizure-drug/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Biopharma sentiment hit a turning point in October",
    "summary": "```json\n{\n  \"summary\": \"A biopharma industry sentiment survey conducted in mid-October revealed an unusual shift in industry mood, marking what appears to be a turning point in overall sector sentimen",
    "url": "https://endpoints.news/biopharma-sentiment-hit-a-turning-point-in-october/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio",
    "summary": "",
    "url": "https://endpoints.news/otr-therapeutics-gets-100m-from-pfizer-ventures-others-to-build-asset-portfolio/",
    "date": "2025-12-05",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "German court stops Merck from selling subcutaneous Keytruda in patent battle with Halozyme",
    "summary": "```json\n{\n  \"summary\": \"A German court has issued an injunction blocking Merck from selling a subcutaneous formulation of Keytruda in Germany. This ruling represents a victory for Halozyme in an ongoi",
    "url": "https://endpoints.news/german-court-stops-merck-from-selling-subcutaneous-keytruda-in-patent-battle-with-halozyme/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "subcutaneous"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Ex-Intercept CEO to take over at Altimmune; Carolyn Bertozzi leaves Alnylam's board",
    "summary": "",
    "url": "https://endpoints.news/ex-intercept-ceo-takes-over-at-altimmune-carolyn-bertozzi-leaves-alnylams-board/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "PAS"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "Praxis stops pivotal trial of rare epilepsy drug early for efficacy",
    "summary": "",
    "url": "https://endpoints.news/praxis-stops-pivotal-trial-of-rare-epilepsy-drug-early-for-efficacy/",
    "date": "2025-12-05",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "A year of scrutiny for health insurers",
    "summary": "",
    "url": "https://endpoints.news/a-year-of-scrutiny-for-health-insurers/",
    "date": "2025-12-04",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__endpoints_news",
    "source_type": "press_sector",
    "title": "ACIP delays vote on hepatitis B birth dose to Friday",
    "summary": "",
    "url": "https://endpoints.news/acip-delays-vote-on-hepatitis-b-birth-dose-to-friday/",
    "date": "2025-12-04",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m\" hreflang=\"en\">Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy\" hreflang=\"en\">Stryker promotes president, COO to help lead its M&amp;A strategy</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study\" hreflang=\"en\">China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine\" hreflang=\"en\">A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device\" hreflang=\"en\">How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle</a>",
    "summary": "```json\n{\n  \"summary\": \"This article discusses how pharmaceutical and biotech companies are leveraging artificial intelligence and real-world evidence to make more informed decisions throughout the dr",
    "url": "https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge\" hreflang=\"en\">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic\" hreflang=\"en\">Amphista's targeted glue sticks the landing in AML test, supporting push into the clinic</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose\" hreflang=\"en\">AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose",
    "date": "2025-12-08",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch\" hreflang=\"en\">ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch</a>",
    "summary": "```json\n{\n  \"summary\": \"Gilead's Kite Pharma presented data at ASH on anito-cel, their next-generation CAR-T therapy for multiple myeloma, positioning it as a potential best-in-class competitor to Car",
    "url": "https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success\" hreflang=\"en\">ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-panel-votes-against-jjs-novel-shunt-implant-heart-failure\" hreflang=\"en\">FDA panel votes against J&amp;J's novel shunt implant for heart failure</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/fda-panel-votes-against-jjs-novel-shunt-implant-heart-failure",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out\" hreflang=\"en\">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>",
    "summary": "```json\n{\n  \"summary\": \"The mRNA industry alliance has issued a statement expressing concern about unprecedented turmoil at the FDA. The coalition warns that instability in FDA leadership is undermini",
    "url": "https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data\" hreflang=\"en\">Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m\" hreflang=\"en\">Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies\" hreflang=\"en\">'Market's thinking is backwards': FDA's 1-trial approval plan would boost R&amp;D spend, Jefferies says</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal\" hreflang=\"en\">Cancer blood test developer Freenome to go public in $330M SPAC deal</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda\" hreflang=\"en\">Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chutes-ladders-yet-another-cder-leadership-shakeup\" hreflang=\"en\">Chutes &amp; Ladders—Yet another CDER leadership shake-up</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-yet-another-cder-leadership-shakeup",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25\" hreflang=\"en\">Fierce Biotech Fundraising Tracker '25: Triana glues together $120M series B; SciNeuro snags $53M</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-ventures-gets-behind-chinese-biotechs-100m-series-boost-rd-hubs-capability\" hreflang=\"en\">Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&amp;D hub's capability</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/pfizer-ventures-gets-behind-chinese-biotechs-100m-series-boost-rd-hubs-capability",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/cro/paradigm-health-raises-78m-revamp-clinical-research-process-inks-deal-roches-flatiron\" hreflang=\"en\">Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche's Flatiron</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/cro/paradigm-health-raises-78m-revamp-clinical-research-process-inks-deal-roches-flatiron",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/ge-healthcare-mayo-clinic-launch-digital-twin-project-personalizing-radiation-cancer\" hreflang=\"en\">GE HealthCare, Mayo Clinic launch digital twin project for personalizing radiation cancer therapy</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/ge-healthcare-mayo-clinic-launch-digital-twin-project-personalizing-radiation-cancer",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/denali-phase-1-pompe-disease-trial-hit-clinical-hold\" hreflang=\"en\">FDA slaps hold on Denali's plans for phase 1 rare disease trial </a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/denali-phase-1-pompe-disease-trial-hit-clinical-hold",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes\" hreflang=\"en\">A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/after-over-20-years-medtronic-claims-deep-brain-stimulation-approval-dystonia\" hreflang=\"en\">After more than 20 years, Medtronic claims deep brain stimulation approval for dystonia</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/after-over-20-years-medtronic-claims-deep-brain-stimulation-approval-dystonia",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025\" hreflang=\"en\">Regulatory tracker: Agios awaits FDA decision as target date passes</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "PAS"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies\" hreflang=\"en\">From data to decisions: how Walgreens is powering smarter pharma strategies</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how\" hreflang=\"en\">Agentic AI can fix healthcare’s communications crisis – here’s how</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers\" hreflang=\"en\">ASH: Regeneron eyes simpler regimens in bid to move bispecifics into earlier blood cancer treatment</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine\" hreflang=\"en\">Beyond the treatment: Innovation on the human side of medicine</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing\" hreflang=\"en\">ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data\" hreflang=\"en\">ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data",
    "date": "2025-12-08",
    "companies_detected": [
      "Novo Nordisk",
      "Pfizer",
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us\" hreflang=\"en\">Lowering FDA fees would spur generics manufacturing in US, Mark Cuban says</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash\" hreflang=\"en\">CDC's ACIP votes to change longstanding hepatitis B vaccine guidance for newborns, prompting backlash </a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out\" hreflang=\"en\">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya\" hreflang=\"en\">AbbVie revs up Skyrizi spending to top TV ad totals in November, edging out J&amp;J's Tremfya</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya",
    "date": "2025-12-08",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026\" hreflang=\"en\">The biopharma dealmaking landscape and what to expect in 2026</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod\" hreflang=\"en\">BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period\" hreflang=\"en\">Avalere Health hires Sarah Hall to lead US marketing team through 'politically dynamic' period</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/mercks-keytruda-sc-launch-germany-faces-new-hurdle-halozyme-scores-preliminary-injunction\" hreflang=\"en\">Merck's Keytruda SC launch in Germany faces new hurdle as Halozyme scores preliminary injunction</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/mercks-keytruda-sc-launch-germany-faces-new-hurdle-halozyme-scores-preliminary-injunction",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight\" hreflang=\"en\">Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cdcs-acip-pushes-back-planned-vote-infant-hepatitis-b-vaccines-confusion-debate-abounds\" hreflang=\"en\">CDC's ACIP pushes back planned vote on newborn hepatitis B vaccines as confusion, debate abound</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/cdcs-acip-pushes-back-planned-vote-infant-hepatitis-b-vaccines-confusion-debate-abounds",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance\" hreflang=\"en\">Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/daiichi-sankyo-receives-fda-untitled-letter-taking-aim-turalio-patient-ambassador-video\" hreflang=\"en\">Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/marketing/daiichi-sankyo-receives-fda-untitled-letter-taking-aim-turalio-patient-ambassador-video",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-churn-and-burn-continues-departure-10-year-director-office-nonprescription-drugs\" hreflang=\"en\">FDA leadership churn continues with transfer of OTC drug office director</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/fda-churn-and-burn-continues-departure-10-year-director-office-nonprescription-drugs",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes\" hreflang=\"en\">A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/quvara-medical-debuts-newest-cdmo-after-group-buys-becton-dickinson-facility\" hreflang=\"en\">Quvara Medical debuts as latest CDMO after Buckland Group buys Becton Dickinson facility</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/manufacturing/quvara-medical-debuts-newest-cdmo-after-group-buys-becton-dickinson-facility",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs\" hreflang=\"en\">After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "XTEN"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/biotech/fda-names-tracy-beth-hoeg-fresh-vaccine-safety-probe-acting-head-drug-center\" hreflang=\"en\">FDA names Tracy Beth Høeg, fresh from vaccine safety probe, as acting head of drug center</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/biotech/fda-names-tracy-beth-hoeg-fresh-vaccine-safety-probe-acting-head-drug-center",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cosmo-shares-zoom-results-2-male-pattern-hair-loss-trials\" hreflang=\"en\">Cosmo shares zoom with results from 2 male-pattern hair loss trials</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/cosmo-shares-zoom-results-2-male-pattern-hair-loss-trials",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-named-as-finalist-in-fierce-innovation-awards-life-sciences-edition-2025/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "summary": "```json\n{\n  \"summary\": \"Nanexa has published its interim financial report covering the January-September 2025 period. This is a routine corporate disclosure providing updates on the company's financia",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "summary": "",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "summary": "",
    "url": "https://storage.mfn.se/5d2c8421-0163-4592-8c9e-43752659a104/nanexa-interim-report-january-june-2025.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Read the presentation",
    "summary": "",
    "url": "https://nanexa.com/wp-content/uploads/2025/11/PODD-Oct-2025.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Videoconference and publication of half-year financial results, Tuesday, December 9, 2025",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_ConfHYR_01122025_EN.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Evercore-Piper_Sandler_EN_27112025.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "[Replay] Jefferies Global Healthcare Conference 2025",
    "summary": "",
    "url": "https://wsw.com/webcast/jeff332/medcl/1970687",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_UBS-STIFEL_06112025_EN_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "summary": "```json\n{\n  \"summary\": \"Teva reports continued strong growth for UZEDY® and announces plans to submit a New Drug Application (NDA) to the US FDA for Olanzapine LAI in Q4 2025. This represents a regula",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [
      "olanzapine"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_Truist_22102025_EN_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [
      "risperidone"
    ],
    "technologies_detected": [
      "XTEN",
      "extended-release injectable"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®",
    "summary": "",
    "url": "https://www.medincell.com/wp-content/uploads/2025/09/MDC_UZEDY-Canada_PR_23092025_vf.pdf",
    "date": "2025-12-08",
    "companies_detected": [
      "MedinCell"
    ],
    "molecules_detected": [
      "risperidone"
    ],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®",
    "summary": "```json\n{\n  \"summary\": \"New data demonstrates that UZEDY® initiation in hospitalized patients leads to faster discharge times compared to Invega Sustenna®. Clinicians showed an overall preference for ",
    "url": "https://www.medincell.com/wp-content/uploads/2025/09/MDC_Psych2025_UZEDY_EN_22092025.pdf",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  }
]